Bone Marrow Transplantation News

Haploidentical stem cell transplantation recipients may achieve similar early immune recovery and clinical outcomes as patients undergoing allogeneic hematopoietic stem cell transplantation with HLA-matched donors, according to the results of a retrospective study.

ASH announced the election of three new members to its executive committee, the governing body of the organization.

Recipients of allogeneic hematopoietic stem cell transplantation faced an increased risk for basal cell carcinoma, squamous cell carcinoma and malignant melanoma, according to the results of a population-based cohort study.

Allogeneic hematopoietic stem cell transplantation may serve as preferred treatment approach for patients aged 60 years or older with intermediate- or adverse-risk acute myeloid leukemia in first remission, according to the results of a time-dependent analysis of four trials.

Pierre Noel, MD, a bone marrow transplant surgeon at Mayo Clinic in Arizona, has been named to the Atlantic Council, a think tank for international affairs.

NEW YORK — Patients with newly diagnosed myeloma who have deletion 17p have a particularly poor prognosis regardless of induction treatment and receipt of autologous stem cell transplantation, according to study results presented at Lymphoma & Myeloma 2015.

Nonmyeloablative HLA-haploidentical blood or marrow transplantation followed by cyclophosphamide demonstrated safety and promising survival outcomes for older patients with hematologic malignancies, according to the results of a retrospective analysis.

Hematopoietic stem cell transplant is a type of procedure that is routinely used to treat patients with cancer as well as other nonmalignant blood and immune disorders, according to the NIH.

The FDA granted priority review to defibrotide, an investigational agent in development for treatment of patients with hepatic veno-occlusive disease who have evidence of multiorgan dysfunction after hematopoietic stem cell transplantation.

The HLA-DPB1 rs9277534 expression marker influenced the risk for graft-versus-host disease associated with HLA-DPB1 mismatching, according to study results published in The New England Journal of Medicine.